Nothing Special   »   [go: up one dir, main page]

WO2006007227A3 - Abnormal cannabidiols for lowering intraocular pressure - Google Patents

Abnormal cannabidiols for lowering intraocular pressure Download PDF

Info

Publication number
WO2006007227A3
WO2006007227A3 PCT/US2005/018830 US2005018830W WO2006007227A3 WO 2006007227 A3 WO2006007227 A3 WO 2006007227A3 US 2005018830 W US2005018830 W US 2005018830W WO 2006007227 A3 WO2006007227 A3 WO 2006007227A3
Authority
WO
WIPO (PCT)
Prior art keywords
intraocular pressure
lowering intraocular
abnormal cannabidiols
formula
cannabidiols
Prior art date
Application number
PCT/US2005/018830
Other languages
French (fr)
Other versions
WO2006007227A2 (en
Inventor
June Chen
David F Woodward
Original Assignee
Allergan Inc
June Chen
David F Woodward
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/874,440 external-priority patent/US20050282912A1/en
Priority claimed from US10/874,441 external-priority patent/US20050282913A1/en
Priority claimed from US11/073,209 external-priority patent/US20050282902A1/en
Priority claimed from US11/121,528 external-priority patent/US20060247321A1/en
Application filed by Allergan Inc, June Chen, David F Woodward filed Critical Allergan Inc
Priority to BRPI0512525-1A priority Critical patent/BRPI0512525A/en
Priority to EP05784443A priority patent/EP1765315A2/en
Priority to JP2007518081A priority patent/JP2008503577A/en
Priority to CA002570853A priority patent/CA2570853A1/en
Publication of WO2006007227A2 publication Critical patent/WO2006007227A2/en
Publication of WO2006007227A3 publication Critical patent/WO2006007227A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the use of Abnormal Cannabidiols as potent ocular hypotensives, and are particular suitable for the management of glaucoma. In particular said compounds are represented by formula (I) or formula (II) or formula (III). These compounds have also been found to be useful in providing neuroprotective effect to the eye.
PCT/US2005/018830 2004-06-22 2005-05-26 Abnormal cannabidiols for lowering intraocular pressure WO2006007227A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
BRPI0512525-1A BRPI0512525A (en) 2004-06-22 2005-05-26 Abnormal cannabidiols as agents for lowering intraocular pressure and providing neuroprotective effect to the eye
EP05784443A EP1765315A2 (en) 2004-06-22 2005-05-26 Abnormal cannabidiols for lowering intraocular pressure
JP2007518081A JP2008503577A (en) 2004-06-22 2005-05-26 Abnormal cannabidiol compounds for reducing intraocular pressure
CA002570853A CA2570853A1 (en) 2004-06-22 2005-05-26 Abnormal cannabidiols for lowering intraocular pressure

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US10/874,440 2004-06-22
US10/874,441 2004-06-22
US10/874,440 US20050282912A1 (en) 2004-06-22 2004-06-22 Abnormal cannabidiols as neuroprotective agents for the eye
US10/874,441 US20050282913A1 (en) 2004-06-22 2004-06-22 Abnormal cannabidiols as agents for lowering intraocular pressure
US11/073,209 US20050282902A1 (en) 2004-06-22 2005-03-05 Abnormal cannabidiols as agents for lowering intraocular pressure
US11/073,209 2005-03-05
US11/121,528 2005-05-02
US11/121,528 US20060247321A1 (en) 2005-05-02 2005-05-02 Abnormal Cannabidiols as agents useful in combination therapy for lowering intraocular pressure

Publications (2)

Publication Number Publication Date
WO2006007227A2 WO2006007227A2 (en) 2006-01-19
WO2006007227A3 true WO2006007227A3 (en) 2006-05-18

Family

ID=35462212

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/018830 WO2006007227A2 (en) 2004-06-22 2005-05-26 Abnormal cannabidiols for lowering intraocular pressure

Country Status (6)

Country Link
EP (1) EP1765315A2 (en)
JP (1) JP2008503577A (en)
AU (1) AU2005262652A1 (en)
BR (1) BRPI0512525A (en)
CA (1) CA2570853A1 (en)
WO (1) WO2006007227A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7618966B2 (en) 2006-04-24 2009-11-17 Allergan, Inc. Abnormal Cannabidiols as agents for lowering intraocular pressure
US7612101B2 (en) 2006-04-24 2009-11-03 Allergan, Inc. Abnormal cannabidiols as agents for lowering intraocular pressure
JP2009536623A (en) * 2006-04-24 2009-10-15 アラーガン、インコーポレイテッド Abnormal cannabidiol compounds as intraocular pressure-lowering agents
US7718830B2 (en) 2006-04-24 2010-05-18 Allergan, Inc. Abnormal cannabidiols as agents for lowering intraocular pressure
CA3091088A1 (en) * 2018-02-13 2019-08-22 Beetlebung Pharma Ltd. Cannabinoid derivatives and conjugates and uses thereof
CN115006404A (en) * 2022-08-09 2022-09-06 昆药集团股份有限公司 Pharmaceutical composition with optic nerve protection effect and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939429A (en) * 1997-09-30 1999-08-17 Virginia Commonwealth University Cardiovascular uses of cannabinoid compounds
WO2001003690A1 (en) * 1999-07-12 2001-01-18 Virginia Commonwealth University Novel vasodilator cannabinoid analogs
WO2003091189A1 (en) * 2002-04-25 2003-11-06 Virginia Commonwealth University Cannabinoids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939429A (en) * 1997-09-30 1999-08-17 Virginia Commonwealth University Cardiovascular uses of cannabinoid compounds
WO2001003690A1 (en) * 1999-07-12 2001-01-18 Virginia Commonwealth University Novel vasodilator cannabinoid analogs
WO2003091189A1 (en) * 2002-04-25 2003-11-06 Virginia Commonwealth University Cannabinoids

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COMPTON, DAVID R. ET AL: "Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogs of 10-substituted cannabidiol and 11- or 12-substituted .DELTA.8-tetrahydrocannabinol", JOURNAL OF MEDICINAL CHEMISTRY , 33(5), 1437-43 CODEN: JMCMAR; ISSN: 0022-2623, 1990, XP001076889 *
HO, W.-S. VANESSA ET AL: "Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery", BRITISH JOURNAL OF PHARMACOLOGY , 138(7), 1320-1332 CODEN: BJPCBM; ISSN: 0007-1188, 2003, XP008060537 *
ULISS, D. B. ET AL: "Hashish. Importance of the phenolic hydroxyl group in tetrahydrocannabinols", JOURNAL OF MEDICINAL CHEMISTRY , 18(2), 213-15 CODEN: JMCMAR; ISSN: 0022-2623, 1975, XP008060536 *

Also Published As

Publication number Publication date
AU2005262652A1 (en) 2006-01-19
WO2006007227A2 (en) 2006-01-19
CA2570853A1 (en) 2006-01-19
EP1765315A2 (en) 2007-03-28
JP2008503577A (en) 2008-02-07
BRPI0512525A (en) 2008-03-11

Similar Documents

Publication Publication Date Title
WO2006044425A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2005002520A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2006062731A8 (en) Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
WO2007108968A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2007076360A8 (en) (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
WO2006101839A3 (en) Enhanced bimatoprost ophthalmic solution
WO2006072393A3 (en) Sulfonyl pyrrolidines, method for producing the same and their use as drugs
WO2006099943A8 (en) Amide-substituted 8-n-benzimidazoles, method for the production thereof, and use of the same as medicaments
WO2006105403A3 (en) Treatment of eye disorders with sirtuin modulators
WO2006127987A3 (en) Treatment of eye disorders with sirtuin modulators
WO2006021379A8 (en) Dihydropteridinone derivatives, methods for the production thereof and their use as medicaments
WO2006021378A8 (en) Dihydropteridinone derivatives, methods for the production thereof and their use as medicaments
EP3542629A3 (en) Dithiol compounds, derivatives, and uses therefor
WO2007120980A3 (en) 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
WO2007062999A3 (en) 1,5-substituted indol-2-yl amide derivatives
WO2007021937A3 (en) Unsaturated heterocyclic derivatives
WO2008040649A3 (en) Pyrazine-2-carboxamide derivatives as cb2 receptor modulators
WO2006072458A3 (en) Substituted oxindole derivatives, medicaments containing said derivatives and use thereof
WO2009111633A3 (en) Mercaptan and seleno-mercaptan compounds and methods of using them
NO20082096L (en) Azaindole-2-karboksamidderivativer
WO2006066950A3 (en) Tricyclic aminoalcohols, methods for producing the same and their use as anti-inflammatory agents
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
WO2006007227A3 (en) Abnormal cannabidiols for lowering intraocular pressure
WO2009074247A8 (en) Novel 2-aryl-thiazole-4-carboxamide derivatives, production thereof, and use thereof as a medicament
WO2005020917A3 (en) Ophthalmic compositions for treating ocular hypertension

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005262652

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2570853

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005784443

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007518081

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

ENP Entry into the national phase

Ref document number: 2005262652

Country of ref document: AU

Date of ref document: 20050526

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005262652

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005784443

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0512525

Country of ref document: BR